Most recently sodium-glucose cotransporter-2 (SGLT-2) inhibitors were the first-in-class therapy to show a benefit in human HFpEF with improvements in HF hospitalization and cardiovascular mortality (6). The gene discussed is SLC5A2; the disease is hydrops fetalis.